Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer

Summary

This phase II trial studies the effect of atezolizumab and bevacizumab before surgery in treating patients with liver cancer that can be removed by surgery (resectable). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Bevacizumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Giving the combination of atezolizumab and bevacizumab may help to prevent liver cancer from returning after surgery.

Timeline

Start

2021-02-10

Primary completion

2027-05-31

Completion

2027-12-31

Drugs

Indications